Liquid biopsy, which analyzes circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) in blood [43, 44], provides a non-invasive approach to assess PIK3CA mutations and monitor treatment response [45, 46]. This evidence concerns the gene PIK3CA and neoplasm.